Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images

Data-efficient and weakly supervised computational pathology on whole-slide images

(2021) Ming Y. Lu et al.   Nature Biomedical Engineering

Epithelium segmentation using deep learning in H&E-stained prostate specimens with immunohistochemistry as reference standard

(2019) Wouter Bulten et al.   Scientific Reports

Applications of machine learning in drug discovery and development

(2019) Jessica Vamathevan et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical-grade computational pathology using weakly supervised deep learning on whole slide images

(2019) Gabriele Campanella et al.   NATURE MEDICINE

Artificial intelligence in digital pathology — new tools for diagnosis and precision oncology

(2019) Kaustav Bera et al.   Nature Reviews Clinical Oncology

Redundant angiogenic signaling and tumor drug resistance

(2018) Rajesh N. Gacche et al.   DRUG RESISTANCE UPDATES

A closer look at cross-validation for assessing the accuracy of gene regulatory networks and models

(2018) Shayan Tabe-Bordbar et al.   Scientific Reports

Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning

(2018) Nicolas Coudray et al.   NATURE MEDICINE

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

(2018) Andrea Varga et al.   GYNECOLOGIC ONCOLOGY

The development and use of vascular targeted therapy in ovarian cancer

(2017) Dana M. Chase et al.   GYNECOLOGIC ONCOLOGY

Fully Convolutional Networks for Semantic Segmentation

(2017) Evan Shelhamer et al.   IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

(2017) Carlos Bais et al.   JNCI-Journal of the National Cancer Institute

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

(2017) Catherine M Phelan et al.   NATURE GENETICS

Roles of tumor heterogeneity in the development of drug resistance: A call for precision therapy

(2017) Duojiao Wu et al.   SEMINARS IN CANCER BIOLOGY

Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses

(2017) Carlos Bais et al.   JNCI-Journal of the National Cancer Institute

Accurate and reproducible invasive breast cancer detection in whole-slide images: A Deep Learning approach for quantifying tumor extent

(2017) Angel Cruz-Roa et al.   Scientific Reports

Anti-angiogenic agents in ovarian cancer: past, present, and future

(2016) B. J. Monk et al.   ANNALS OF ONCOLOGY

Locality Sensitive Deep Learning for Detection and Classification of Nuclei in Routine Colon Cancer Histology Images

(2016) Korsuk Sirinukunwattana et al.   IEEE TRANSACTIONS ON MEDICAL IMAGING

State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer

(2015) Whitney Graybill et al.   GYNECOLOGIC ONCOLOGY

GnRH and GnRH receptors in the pathophysiology of the human female reproductive system

(2015) Roberto Maggi et al.   HUMAN REPRODUCTION UPDATE

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial

(2015) Amit M Oza et al.   LANCET ONCOLOGY

Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab

(2014) Karina Dahl Steffensen et al.   EUROPEAN JOURNAL OF CANCER

Breast Cancer Histopathology Image Analysis: A Review

(2014) Mitko Veta et al.   IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING

The challenge of intratumour heterogeneity in precision medicine

(2014) J. Seoane et al.   JOURNAL OF INTERNAL MEDICINE

Markers of Response for the Antiangiogenic Agent Bevacizumab

(2013) Diether Lambrechts et al.   JOURNAL OF CLINICAL ONCOLOGY

Latest research and treatment of advanced-stage epithelial ovarian cancer

(2013) Robert L. Coleman et al.   Nature Reviews Clinical Oncology

Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancer

(2012) Bradley J. Monk et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Changes in Tumor Blood Flow as Measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) May Predict Activity of Single Agent Bevacizumab in Recurrent Epithelial Ovarian (EOC) and Primary Peritoneal Cancer (PPC) Patients: An exploratory analysis of a Gynecologic Oncology Group Phase II study

(2012) Dana M. Chase et al.   GYNECOLOGIC ONCOLOGY

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

(2012) Carol Aghajanian et al.   JOURNAL OF CLINICAL ONCOLOGY

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

(2011) Samar Masoumi Moghaddam et al.   CANCER AND METASTASIS REVIEWS

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

(2011) Robert A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model

(2008) S. Mabuchi et al.   CLINICAL CANCER RESEARCH